Nano-X Imaging Ltd. NNOX R2K
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. It provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source; and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists; Nanox.CONNECT to receive local regulatory approvals and explore and evaluate the business model and the potential service; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data of existing computed tomography scans; and Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers and mobile imaging service providers, urgent care facilities, and multi-specialty physician groups. In addition, the company provides Real+ Osteoporosis Care Management Platform, a osteoporosis care management software platform; AI-Based Aortic Valve Calcification Measurement, an artificial intelligencebased solution; AI-Based Body Composition Measurement, an artificial intelligencebased body composition analysis capability; and Nanox Health IT, a healthcare information technology services provider that serves hospitals and other healthcare organizations. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Petah Tikva, Israel.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 14.9% over 5 years.
- Profit CAGR of 11.3% over 5 years.
CONS
- Trading 65.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NNOX Nano-X Imaging Ltd. R2K | 1.92 | - | $133.61M | - | -41.78% | -45.62% | 14.93% | 11.25% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 3.00M | 2.81M | 3.04M | 3.45M | 3.72M |
| Cost of Revenue | - | 5.89M | 5.86M | 6.28M | 6.33M | 7.34M |
| Gross Profit | - | -2.89M | -3.05M | -3.24M | -2.88M | -3.62M |
| Operating Expenses | - | 12.09M | 11.04M | 11.25M | 11.35M | 14.27M |
| Operating Income | - | -14.97M | -14.09M | -14.49M | -14.23M | -17.88M |
| EBITDA | - | -12.04M | -11.15M | -11.54M | -11.28M | -15.04M |
| Interest Expense | - | - | - | 149.00K | - | - |
| Pretax Income | - | -14.15M | -13.32M | -14.64M | -13.78M | -35.07M |
| Tax Provision | - | -94.00K | -86.00K | 82.00K | -94.00K | -1.69M |
| Net Income | - | -14.06M | -13.24M | -14.72M | -13.68M | -33.37M |
| Diluted EPS | - | -0.23 | -0.21 | -0.23 | -0.21 | -0.50 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 8.58M | 9.90M | 11.28M | 13.02M |
| Cost of Revenue | - | 15.46M | 16.50M | 21.89M | 25.81M |
| Gross Profit | - | -6.88M | -6.59M | -10.61M | -12.79M |
| Operating Expenses | - | 80.33M | 53.06M | 46.14M | 47.91M |
| Operating Income | - | -87.21M | -59.66M | -56.75M | -60.70M |
| EBITDA | - | -75.70M | -47.85M | -45.01M | -49.00M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -116.92M | -61.12M | -53.87M | -76.81M |
| Tax Provision | - | -3.68M | -339.00K | -358.00K | -1.79M |
| Net Income | - | -113.24M | -60.78M | -53.52M | -75.02M |
| Diluted EPS | - | -2.01 | -1.08 | -0.91 | -1.16 |
Compounded Sales Growth
| 5 Years: | 14.93% |
| 1 Year: | 24.00% |
Compounded Profit Growth
| 5 Years: | 11.25% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -62.50% |
| 6 Months: | -57.52% |
| 3 Months: | -18.99% |
| 1 Month: | +12.28% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 253.93M | 218.65M | 210.00M | 162.16M |
| Current Assets | - | 82.46M | 88.64M | 78.68M | 66.79M |
| Cash & Equivalents | - | 38.46M | 56.38M | 39.30M | 49.15M |
| Inventory | - | 0 | 2.36M | 1.49M | 3.07M |
| Receivables | - | 977.00K | 1.48M | 1.80M | 2.01M |
| Total Liabilities | - | 37.25M | 23.13M | 20.88M | 22.43M |
| Current Liabilities | - | 25.07M | 15.52M | 13.97M | 16.89M |
| Long Term Debt | 3.80M | 3.48M | - | - | - |
| Total Debt | - | 4.62M | 8.40M | 7.45M | 7.85M |
| Total Equity | - | 216.68M | 195.51M | 189.12M | 139.73M |
| Shares Outstanding | - | 55.09M | 57.78M | 63.76M | 69.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -43.38M | -44.78M | -36.60M | -40.79M |
| Investing Cash Flow | - | 14.61M | 35.43M | -20.05M | 29.37M |
| Financing Cash Flow | - | 804.00K | 27.25M | 39.50M | 21.37M |
| Capital Expenditure | - | -7.17M | -3.30M | -2.77M | -4.21M |
| Free Cash Flow | - | -50.56M | -48.08M | -39.37M | -45.00M |
| Net Change in Cash | - | -27.98M | 17.91M | -17.14M | 9.95M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -80.2% | -66.6% | -94.0% | -98.2% |
| Operating Margin % | - | -1,016.6% | -602.3% | -502.9% | -466.2% |
| Net Margin % | - | -1,320.2% | -613.6% | -474.3% | -576.1% |
| ROE % | - | -52.3% | -31.1% | -28.3% | -53.7% |
| ROCE % | - | -38.1% | -29.4% | -28.9% | -41.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.49% | 3.82M | $7.33M |
| 2 | Weiss Asset Management Lp | 4.01% | 2.79M | $5.36M |
| 3 | UBS Group AG | 1.94% | 1.35M | $2.59M |
| 4 | State Street Corporation | 1.75% | 1.22M | $2.34M |
| 5 | Geode Capital Management, LLC | 1.28% | 893.10K | $1.71M |
| 6 | ARK Investment Management, LLC | 1.05% | 733.29K | $1.41M |
| 7 | National Bank of Canada/FI/ | 0.82% | 573.03K | $1.10M |
| 8 | Northern Trust Corporation | 0.75% | 524.29K | $1.01M |
| 9 | AQR Capital Management, LLC | 0.71% | 494.69K | $949.81K |
| 10 | Bank of America Corporation | 0.70% | 484.33K | $929.91K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NNOX